BioCorp’s Value Chain Excellence Strengthened Through The Extension Of International Quality Certifications

Published: Apr 27, 2017

ISSOIRE, France--()--Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA-PME eligible), a French company specializing in the development and manufacturing of medical devices and smart-drug delivery systems, today announces the renewal and extension of international quality certifications strengthening the excellence of its entire value chain.

ISO 9001:2008, NF EN ISO 13485:2012 and NF EN ISO 15378:2012 certificates which already covered BIOCORP’s production activities have been renewed. The company also extended the application of the NF EN ISO 13485:2012 certificate which now covers BIOCORP’s global expertise from designing medical devices to developing health platforms and mobile applications.

With over 20 years of experience, 30 million units produced each year and 15 patent families, BIOCORP is a leading player evolving at the core of the evolution of issuance systems and offering innovative solutions to meet new patients’ needs. After successfully developing its business offer and achieving advances in pharmaceutical and connected medical devices, BIOCORP again confirms its know-how and excellence through the renewal of these international certifications, which now cover all of its development and production activities. It also confirms BIOCORP’s recognized expertise in the implementation of complex projects at the highest level of quality.

“The renewal and extension of international quality certifications to our entire value chain confirm BIOCORP’s expertise in the development of both traditional and connected medical devices. We are very pleased to receive this recognition made possible through the contribution of our teams. It also underlines BIOCORP’s professionalization process and will be an additional asset when answering often complex requests from our clients, both from a regulatory and a quality point of view”, said Jacques Gardette and Eric Dessertenne, respectively founder and CEO, and Chief Operating Officer of BIOCORP.

ABOUT BIOCORP

Founded in 2004 in Issoire (near Clermont-Ferrand), France, BIOCORP is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, BIOCORP is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, BIOCORP continues to innovate in the area of medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internet-connected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 48 employees.
BIOCORP is listed on Alternext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit: www.biocorp.fr
Follow us on Twitter @BIOCORPSystems

BIOCORP
Jacques Gardette
CEO
Eric Dessertenne
Chief Operating Officer
investisseurs@biocorp.fr
or
Press relations
ALIZE RP
Caroline Carmagnol & Wendy Rigal
+33 (0)1 44 54 36 66 / +33 (0)6 48 82 18 94
biocorp@alizerp.com

Back to news